An inhibitor of PDE5, tadalafil, has been demonstrated to have a dramatic and durable anti-myeloma immune and clinical response in a patient with end-stage relapsed/refractory MM (Noonan et al., 2014). The gene discussed is PDE5A; the disease is Miyoshi myopathy.